1.
Pappas P., Rex J., Sobel J., et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38:161-89.
2.
Веселов А.В. Ведение пациентов с кандидозом: обзор новых рекомендаций IDSA. Clinical Microbiology and Antimicrobial Chemotherapy.2004; 6:168-85.
3.
Каспофунгин – первый противогрибковый препарат из группы эхинокандинов. Clinical Microbiology and Antimicrobial Chemotherapy.2003; 5:32-4.
4.
Mora-Duarte J., Betts R., Rotstein R., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020-9.
5.
Kojic E.M., Darouiche R.O. Candida infection of medical devices. Clin Micribiol Rev 2004; 17:255-67.
6.
Ullmann A.J. Review of the safety, tolerability, and drug interaction of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin 2003; 19:263-71.
7.
Arathoon E.G., Gotuzzo E., Noriega L.M., et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002; 46:451-7.
8.
Kartsonis N., DiNubile M.J., Bartizal K., et al. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acq Immune Defic Syndrome Hum Retrovirol 2002; 31:183-7.
9.
De Pauw B., Sable C., Walsh T., et al. Impact of resolution of fever on the overall composite endpoint in a phase III study of caspofungin vs. liposomal amphotericin B as empirical therapy for neutropenic patients with persistent fever. Proceedings of 14th ECCMID; Prague, 2004. Abstr. 0423.
10.
Mattiuzzi G.N., Kantarjian H., Alvarado G., et al. Intravenous itraconazole vs. caspofungin prophylaxis in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Proceedings of 43rd ICAAC, Chicago, 2003. Abstr. M-984.
11.
Sora F., Chiusolo P., Piccirillo N. et al. Successful treatment with caspofungin of hepatosplenic candidiasis resistant to liposomal amphotericin B. Clin Infect Dis 2002; 35:1135-6.